Beyond the jab: A need for global coordination of pharmacovigilance for COVID-19 vaccine deployment.
作者信息
Naniche Denise, Hotez Peter, Bottazzi Maria Elena, Ergonul Onder, Figueroa J Peter, Gilbert Sarah, Gursel Mayda, Hassanain Mazen, Kang Gagandeep, Kaslow David, Kim Jerome H, Lall Bhavna, Larson Heidi, Sheahan Timothy, Shoham Shmuel, Wilder-Smith Annelies, Sow Samba O, Strub-Wourgaft Nathalie, Yadav Prashant, Batista Carolina
机构信息
ISGlobal-Barcelona Institute for Global Health-Hospital Clinic-University of Barcelona, Spain.
Texas Children's Center for Vaccine Development, Baylor College of Medicine, Houston, TX, USA.
出版信息
EClinicalMedicine. 2021 Jun;36:100925. doi: 10.1016/j.eclinm.2021.100925. Epub 2021 Jun 3.
Abstract
摘要
相似文献
1
Beyond the jab: A need for global coordination of pharmacovigilance for COVID-19 vaccine deployment.注射疫苗之外：新冠疫苗部署中全球药物警戒协调的必要性
EClinicalMedicine. 2021 Jun;36:100925. doi: 10.1016/j.eclinm.2021.100925. Epub 2021 Jun 3.
2
Impact of Australian mandatory 'No Jab, No Pay' and 'No Jab, No Play' immunisation policies on immunisation services, parental attitudes to vaccination and vaccine uptake, in a tertiary paediatric hospital, the Royal Children's Hospital, Melbourne.澳大利亚强制性“无疫苗，无报酬”和“无疫苗，无玩耍”免疫政策对免疫服务、父母对疫苗接种的态度以及疫苗接种率的影响，在墨尔本的三级儿科医院——皇家儿童医院。
Vaccine. 2020 Jul 14;38(33):5231-5240. doi: 10.1016/j.vaccine.2020.05.094. Epub 2020 Jun 17.
3
Parental opinions towards the "No Jab, No Pay" policy in Australia.家长对澳大利亚“无疫苗，无补贴”政策的看法。
Vaccine. 2019 Aug 23;37(36):5250-5256. doi: 10.1016/j.vaccine.2019.07.066. Epub 2019 Jul 29.
4
Guide to active vaccine safety surveillance: Report of CIOMS working group on vaccine safety - executive summary.活性疫苗安全性监测指南：国际医学科学组织委员会疫苗安全工作组报告——执行摘要
Vaccine. 2017 Jul 13;35(32):3917-3921. doi: 10.1016/j.vaccine.2017.06.033. Epub 2017 Jun 20.
5
Capacity for a global vaccine safety system: the perspective of national regulatory authorities.全球疫苗安全体系的能力：国家监管机构的观点。
Vaccine. 2012 Jul 13;30(33):4953-9. doi: 10.1016/j.vaccine.2012.05.045. Epub 2012 May 30.
6
Landscape analysis of pharmacovigilance and related practices among 34 vaccine manufacturers' from emerging countries.新兴国家 34 家疫苗制造商的药物警戒及相关实践的景观分析。
Vaccine. 2020 Jul 22;38(34):5490-5497. doi: 10.1016/j.vaccine.2020.06.016. Epub 2020 Jun 24.
7
[Not Available].[无可用内容]。
Sante Publique. 2017 Nov-Dec;29(6):921-925. doi: 10.3917/spub.176.0921.
8
The Role of Pharmacovigilance and ISoP During the Global COVID-19 Pandemic.药物警戒与国际药物警戒规范在全球新冠疫情期间的作用
Drug Saf. 2020 Jun;43(6):511-512. doi: 10.1007/s40264-020-00941-4.
9
Effective vaccine safety systems in all countries: a challenge for more equitable access to immunization.所有国家建立有效的疫苗安全体系：实现更公平获得免疫接种的挑战。
Vaccine. 2013 Apr 18;31 Suppl 2:B108-14. doi: 10.1016/j.vaccine.2012.10.119.
10
Nucleoside-modified messenger RNA COVID-19 vaccine platform.核苷修饰的信使 RNA COVID-19 疫苗平台。
J Med Virol. 2021 Jul;93(7):4054-4057. doi: 10.1002/jmv.26924. Epub 2021 Mar 25.
引用本文的文献
1
Pharmacovigilance in Vaccines: Importance, Main Aspects, Perspectives, and Challenges-A Narrative Review.疫苗的药物警戒：重要性、主要方面、前景与挑战——一篇叙述性综述
Pharmaceuticals (Basel). 2024 Jun 19;17(6):807. doi: 10.3390/ph17060807.
2
Obesity and its Relationship with Covid-19: A Review of the Main Pharmaceutical Aspects.肥胖与新冠肺炎的关系：主要药物学方面的综述。
Curr Pharm Biotechnol. 2024;25(13):1651-1663. doi: 10.2174/0113892010264503231108070917.
3
Oral adverse events following COVID-19 and influenza vaccination in Australia.澳大利亚 COVID-19 和流感疫苗接种后的口腔不良事件。
Hum Vaccin Immunother. 2023 Aug;19(2):2253589. doi: 10.1080/21645515.2023.2253589. Epub 2023 Sep 21.
4
The Association of Psychosocial Manifestations and Quality of Life With Inflammatory Markers in SARS-CoV-2 Patients: A Study From a Dedicated COVID-19 Tertiary Care Hospital.新冠病毒患者心理社会表现及生活质量与炎症标志物的关联：来自一家专门的新冠病毒三级护理医院的研究
Cureus. 2023 Jul 23;15(7):e42341. doi: 10.7759/cureus.42341. eCollection 2023 Jul.
5
Factors, enablers and challenges for COVID-19 vaccine development.新冠疫苗研发的影响因素、助力因素和挑战。
BMJ Glob Health. 2023 Jun;8(6). doi: 10.1136/bmjgh-2023-011879.
6
A Call to Enhance Active and Transparent Pharmacovigilance for COVID-19 Vaccines.呼吁加强新冠疫苗主动和透明的药物警戒
Oman Med J. 2023 May 31;38(3):e520. doi: 10.5001/omj.2023.81. eCollection 2023 May.
7
A Qualitative Study of Stakeholders' Views on Pharmacovigilance System, Policy, and Coordination in Pakistan.关于巴基斯坦利益相关者对药物警戒系统、政策及协调的观点的定性研究
Front Pharmacol. 2022 Jun 9;13:891954. doi: 10.3389/fphar.2022.891954. eCollection 2022.
8
Accelerating research and development of new vaccines against tuberculosis: a global roadmap.加速结核病新型疫苗的研发：全球路线图。
Lancet Infect Dis. 2022 Apr;22(4):e108-e120. doi: 10.1016/S1473-3099(21)00810-0. Epub 2022 Feb 28.
9
Predictors of COVID-19 Vaccine Confidence: Findings from Slums of Four Major Metro Cities of India.新冠疫苗信心的预测因素：来自印度四大都市贫民窟的调查结果
Vaccines (Basel). 2021 Dec 31;10(1):60. doi: 10.3390/vaccines10010060.
10
Global public health security and justice for vaccines and therapeutics in the COVID-19 pandemic.全球公共卫生安全与新冠疫情中疫苗和治疗方法的公平分配
EClinicalMedicine. 2021 Sep;39:101053. doi: 10.1016/j.eclinm.2021.101053. Epub 2021 Aug 3.
本文引用的文献
1
Access to and equitable distribution of COVID-19 vaccine in low-income countries.低收入国家获取和公平分配新冠疫苗的情况。
NPJ Vaccines. 2021 Apr 14;6(1):54. doi: 10.1038/s41541-021-00323-6.
2
Correcting COVID-19 vaccine misinformation: Lancet Commission on COVID-19 Vaccines and Therapeutics Task Force Members.纠正新冠病毒疫苗错误信息：《柳叶刀》新冠病毒疫苗与治疗委员会特别工作组成员
EClinicalMedicine. 2021 Mar;33:100780. doi: 10.1016/j.eclinm.2021.100780. Epub 2021 Mar 6.
3
We have to get it right: Ensuring success.我们必须把它做好：确保成功。
EClinicalMedicine. 2021 Jan;31:100690. doi: 10.1016/j.eclinm.2020.100690. Epub 2020 Dec 10.
4
Potential effects of vaccinations on the prevention of COVID-19: rationale, clinical evidence, risks, and public health considerations.疫苗接种对预防 COVID-19 的潜在影响：基本原理、临床证据、风险和公共卫生考虑。
Expert Rev Vaccines. 2020 Oct;19(10):919-936. doi: 10.1080/14760584.2020.1825951. Epub 2020 Oct 6.
Zotero 插件